5,405
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Tapentadol Prolonged Release in Patients with Chronic low back Pain: Real-World Data from the German Pain eRegistry

ORCID Icon, ORCID Icon, , , , & show all
Pages 211-227 | Received 21 Jun 2021, Accepted 20 Jul 2021, Published online: 11 Aug 2021

Figures & data

Figure 1. Data selection.

PR: Prolonged release.

Figure 1. Data selection.PR: Prolonged release.

Table 1. Baseline characteristics (n = 2331 in each group).

Table 2. Previous and concomitant analgesic medications (n = 2331 in each group).

Figure 2. Newly initiated treatment of adjuvant analgesics during the observation period.

PR: Prolonged release.

Figure 2. Newly initiated treatment of adjuvant analgesics during the observation period.PR: Prolonged release.
Figure 3. Change in main effectiveness parameters over the evaluation period.

*p < 0.001 in favor of tapentadol PR.

BL: Baseline; mPDI: Modified pain disability index; PR: Prolonged release; SF: Short form; VAS: Visual analogue scale; W: Week.

Figure 3. Change in main effectiveness parameters over the evaluation period.*p < 0.001 in favor of tapentadol PR.BL: Baseline; mPDI: Modified pain disability index; PR: Prolonged release; SF: Short form; VAS: Visual analogue scale; W: Week.

Table 3. Mean changes in pain intensity over the evaluation period (n = 2331 in each group).

Figure 4. Change in pain-related impairment of sleep over the observation period.

*p < 0.001 in favor of tapentadol PR.

mPDI: Modified pain disability index; PR: Prolonged release; VAS: Visual analogue scale; W: Week.

Figure 4. Change in pain-related impairment of sleep over the observation period.*p < 0.001 in favor of tapentadol PR.mPDI: Modified pain disability index; PR: Prolonged release; VAS: Visual analogue scale; W: Week.
Figure 5. Change in pain phenomenology over the observation period.

(A) Mean PDQ7 score. (B) Pain components.

*p < 0.001 in favor of tapentadol PR.

BL: Baseline; PDQ: PainDETECT questionnaire; PR: Prolonged release; W: Week.

Figure 5. Change in pain phenomenology over the observation period. (A) Mean PDQ7 score. (B) Pain components.*p < 0.001 in favor of tapentadol PR.BL: Baseline; PDQ: PainDETECT questionnaire; PR: Prolonged release; W: Week.
Figure 6. Change in bowel function over the observation period.

A BFI reference range of 0–28.8 indicates normal bowel function.

BFI: Bowel function index; BL: Baseline; PR: Prolonged release; VAS: Visual analogue scale; W: Week.

Reproduced with permission from the International Association for the Study of Pain [Citation40].

Figure 6. Change in bowel function over the observation period.A BFI reference range of 0–28.8 indicates normal bowel function.BFI: Bowel function index; BL: Baseline; PR: Prolonged release; VAS: Visual analogue scale; W: Week.Reproduced with permission from the International Association for the Study of Pain [Citation40].

Table 4. Drug-related adverse events during the 12-week observation period (n = 2331 in each group).

Figure 7. Responder analysis.

The primary end point included the three dimensions: tolerability, effectiveness and safety. A treatment responder had to fulfil the tolerability criterion and the safety criterion plus at least two criteria from the dimension effectiveness.

DRAE: Drug-related adverse event; PR: Prolonged release; QoL: Quality of life.

Figure 7. Responder analysis.The primary end point included the three dimensions: tolerability, effectiveness and safety. A treatment responder had to fulfil the tolerability criterion and the safety criterion plus at least two criteria from the dimension effectiveness.DRAE: Drug-related adverse event; PR: Prolonged release; QoL: Quality of life.